Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chemotherapy

Failure of bevacizumab in early-stage colon cancer

A randomized phase III trial of patients with stage II and III colon cancer showed no benefit of adding bevacizumab to standard adjuvant oxaliplatin plus fluorouracil and leucovorin. Despite suggestive evidence of a short-term benefit, these data and other similar findings dictate that adjuvant bevacizumab should not be used in colon cancer.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).

    CAS  Article  Google Scholar 

  2. Moertel, C. G. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352–358 (1990).

    CAS  Article  Google Scholar 

  3. Andre, T. et al. Oxaliplatin, 5-fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343–2351 (2004).

    CAS  Article  Google Scholar 

  4. Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. doi:10.1200/JCO.2010.30.0855.

    CAS  Article  Google Scholar 

  5. Sargent, D. J. et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23, 8664–8670 (2005).

    Article  Google Scholar 

  6. Investor Update. Roche provides results on Avastin in adjuvant colon cancer [online], (2010).

  7. Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117–3125 (2009).

    CAS  Article  Google Scholar 

  8. Alberts, S. R. et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage II colon cancer (CC): results from NCCTG intergroup phase III trial N0147 [abstract CRA3507]. J. Clin. Oncol. 28 (Suppl. 18), 959s (2010).

    Google Scholar 

  9. University of Birmingham. FOxTROT [online], (2010).

  10. Quasar Collaborative Group et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370, 2020–2029 (2007).

Download references

Acknowledgements

The author would like to thank Dr. Axel Grothey for helpful discussions.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

D. J. Sargent declares that he has previously acted as a consultant for Genentech.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sargent, D. Failure of bevacizumab in early-stage colon cancer. Nat Rev Clin Oncol 8, 10–11 (2011). https://doi.org/10.1038/nrclinonc.2010.205

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.205

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing